Literature DB >> 14968106

Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.

B Jordan1, Y Pasquier, A Schnider.   

Abstract

STUDY
DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.
OBJECTIVE: To describe the pathology and the rehabilitation of an uncommon complication of intrathecal drug administration during the oncologic treatment of acute lymphoma.
SETTING: Spinal cord rehabilitation center, University Hospital.
METHOD: Clinical and radiological observations during a rehabilitation program.
RESULTS: Evidence of neurological improvement and rehabilitation potential after severe myelopathy due to intrathecal injection of doxorubicin.
CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin. Despite early complete paraplegia, some neurological and functional recovery was observed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14968106     DOI: 10.1038/sj.sc.3101592

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  3 in total

1.  StemPanTox: A fast and wide-target drug assessment system for tailor-made safety evaluations using personalized iPS cells.

Authors:  Junko Yamane; Takumi Wada; Hironori Otsuki; Koji Inomata; Mutsumi Suzuki; Tomoka Hisaki; Shuichi Sekine; Hirokazu Kouzuki; Kenta Kobayashi; Hideko Sone; Jun K Yamashita; Mitsujiro Osawa; Megumu K Saito; Wataru Fujibuchi
Journal:  iScience       Date:  2022-06-06

Review 2.  Dorsal column myelopathy following intrathecal chemotherapy for acute lymphoblastic leukemia.

Authors:  Prathap Jacob Joseph; Maria Regina Reyes
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

Review 3.  Neuraxial and peripheral misconnection events leading to wrong-route medication errors: a comprehensive literature review.

Authors:  Eugene R Viscusi; Vincent Hugo; Klaus Hoerauf; Frederick S Southwick
Journal:  Reg Anesth Pain Med       Date:  2020-11-03       Impact factor: 6.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.